Axsome Therapeutics (Axsome Therapeutics) Total Inventories : $15.1 Mil (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Axsome Therapeutics Total Inventories?

Axsome Therapeutics's total inventories for the quarter that ended in Dec. 2023 was $15.1 Mil. Axsome Therapeutics's average total inventories from the quarter that ended in Sep. 2023 to the quarter that ended in Dec. 2023 was $12.6 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Axsome Therapeutics's Net-Net Working Capital per share for the quarter that ended in Dec. 2023 was $1.43.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Axsome Therapeutics's Days Inventory for the three months ended in Dec. 2023 was 155.34.

Inventory Turnover measures how fast the company turns over its inventory within a year. Axsome Therapeutics's Inventory Turnover for the quarter that ended in Dec. 2023 was 0.59.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Axsome Therapeutics's Inventory-to-Revenue for the quarter that ended in Dec. 2023 was 0.18.

Axsome Therapeutics Total Inventories Historical Data

The historical data trend for Axsome Therapeutics's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Axsome Therapeutics Total Inventories Chart

Axsome Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Inventories

Get a 7-Day Free Trial

4.32

15.14

Axsome Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Inventories	Get a 7-Day Free Trial															4.32	7.94	9.25	9.99	15.14

Axsome Therapeutics Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

Axsome Therapeutics (NAS:AXSM) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Axsome Therapeutics's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2023 is

	Net-Net Working Capital Per Share (Q: Dec. 2023 )
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(386.193	+	0.75 * 94.82	+	0.5 * 15.135	-	397.259
-	0	-	0)	/	47.3514
=	1.43

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Axsome Therapeutics's Days Inventory for the three months ended in Dec. 2023 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Dec. 2023 )	/	Cost of Goods Sold (Q: Dec. 2023 )	*	Days in Period
	=	12.56	/	7.378	*	365 / 4
	=	155.34

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Axsome Therapeutics's Inventory Turnover for the quarter that ended in Dec. 2023 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Dec. 2023 )	/	Average Total Inventories (Q: Dec. 2023 )
	=	7.378	/	12.56
	=	0.59

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Axsome Therapeutics's Inventory to Revenue for the quarter that ended in Dec. 2023 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	12.56	/	71.53
	=	0.18

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

Axsome Therapeutics Total Inventories Related Terms

Thank you for viewing the detailed overview of Axsome Therapeutics's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.

Axsome Therapeutics (Axsome Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Axsome Therapeutics Inc (NAS:AXSM) » Definitions » Total Inventories

Comparable Companies

Traded in Other Exchanges

19X:Germany 19X:Germany

Address

22 Cortlandt Street, 16th Floor, New York, NY, USA, 10007

Website

https://www.axsome.com

Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14.

Executives

Susan Mahony	director	LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Mark Coleman	director	25 BROADWAY, 9TH FLOOR, NEW YORK NY 10004
Hunter R. Murdock	officer: General Counsel	22 CORTLAND STREET, 16TH FLOOR, NEW YORK NY 10007
Roger Jeffs	director
Nick Pizzie	officer: Chief Financial Officer	25 BROADWAY, 9TH FLOOR, NEW YORK NY 10004
Mark E Saad	director	C/O CYTORI THERAPEUTICS, INC., 3020 CALLAN ROAD, SAN DIEGO CA 92121
Herriot Tabuteau	director, 10 percent owner, officer: CHIEF EXECUTIVE OFFICER
Mark L. Jacobson	officer: Chief Operating Officer	200 BROADWAY, 3RD FLOOR, NEW YORK NY 10038
David C Marek	officer: Chief Commercial Officer	C/O WEBMD HEALTH CORP., 111 EIGHTH AVENUE, NEW YORK NY 10011
John Golubieski	officer: Chief Financial Officer	C/O LANTHEUS HOLDINGS, INC., 331 TREBLE COVE ROAD, NORTH BILLERICA NY 01862
Myrtle S Potter	director	10 FINDERNE AVE, BRIDGEWATER NJ 08807
Randall Kaye	officer: Chief Medical Officer	11388 SORRENTO VALLEY ROAD, STE. 200, SAN DIEGO CA 92121
Ames Constance	officer: Vice President, Finance	25 BROADWAY, 9TH FLOOR, NEW YORK NY 10004
Antecip Capital Llc	10 percent owner	630 5TH AVENUE, SUITE 2074, NEW YORK NY 10111